Incyte Corp
NASDAQ: INCY
$80.48
-$0.10 (-0.1%)
Closing Price on November 13, 2024
INCY Articles
Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead money until something happens.
Published:
Last Updated:
24/7 Wall St. has put together a preview of Express Scripts, T-Mobile and some of the other most anticipated quarterly earnings reports that are on deck for Tuesday.
Published:
Last Updated:
Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte.
Published:
Last Updated:
Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
Published:
Last Updated:
Stocks have pulled back off their highs from the end of 2016 and that Dow Jones Industrial Average (DJIA) 20,000 mark remains elusive. The major market indexes were indicated a tad lower on Monday,...
Published:
Last Updated:
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Published:
Last Updated:
A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.
Published:
Last Updated:
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Published:
Last Updated:
The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive, with investors feeling much better than a few months ago.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 23, include Charles Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration and Nike.
Published:
Last Updated:
Despite the market rally, insiders are still buying at big levels, while insider selling remains dormant. This is a very positive sign for equity investors and the market as a whole.
Published:
Last Updated:
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
Published:
Last Updated:
Incyte reported better-than-expectged fourth-quarter financial results after the markets closed on Wednesday.
Published:
Last Updated: